TLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TriSalus Life Sciences Inc (TLSI) is not a strong buy at the moment for a beginner, long-term investor. While the company has shown significant revenue growth, its financials remain weak with a declining net income and EPS. The technical indicators suggest a neutral to bearish trend, and there are no strong positive catalysts or trading signals to support an immediate buy decision. Given the investor's preference for long-term investments, it would be prudent to monitor the stock for better entry points or stronger signs of financial and operational improvement.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is in the neutral zone, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a weak overall trend. Key resistance levels are at 4.222 and 4.385, with support at 3.695 and 3.532.
Revenue increased by 59.85% YoY in Q4 2025, and gross margin improved slightly to 86.66%. Analysts maintain positive ratings (Outperform/Buy) despite lowering price targets.
Net income dropped by -10.45% YoY, and EPS declined significantly by -47.50% YoY. No recent news or significant trading trends from hedge funds, insiders, or Congress. Technical indicators show a bearish moving average trend.
In Q4 2025, revenue grew to $13.2M (+59.85% YoY), but net income fell to -$9.75M (-10.45% YoY), and EPS dropped to -0.21 (-47.50% YoY). Gross margin improved slightly to 86.66%.
Analysts have lowered price targets recently, with Northland reducing it to $8 from $12.50 and Canaccord lowering it to $7 from $12. Both analysts maintain positive ratings (Outperform/Buy) but highlight a more measured growth trajectory and backend-loaded expectations for 2026.
